Clinical Trials Logo

Clinical Trial Summary

Short gut syndrome with intestinal failure patients may have decreased production of disaccharidases, like sucrase, an enzyme responsible for digesting sugar in foods. This can happen due to loss of bowel length from surgery or from loss of cellular function in the intestines due to use of parenteral nutrition intravenously. Therefore, patients with these conditions may not be able to digest sucrose (sugar) fully. Patients might experience abdominal distension/pain, vomiting and diarrhea when sugar is taken in orally or through the g-tube, which can limit patients' ability to increase oral or g-tube feeds in short gut syndrome patients with intestinal failure. In patients with short gut syndrome and intestinal failure, the administration of exogenous sucrase (enzyme) may improve sucrose (sugar) digestion and thus the ability to tolerate more oral or g-tube feeds.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04604275
Study type Interventional
Source University of Miami
Contact Amanda Fifi, MD
Phone 3052433166
Email afifi@med.miami.edu
Status Recruiting
Phase Phase 2
Start date February 2, 2022
Completion date January 1, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04522778 - Innovative Central Line Securement Device in the Pediatric Population N/A
Recruiting NCT05432648 - Fiber Food Introduction in Pediatric Short Bowel Syndrome N/A
Withdrawn NCT02246816 - A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 Phase 3
Withdrawn NCT02242656 - A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals Phase 3
Enrolling by invitation NCT06240065 - Predicting Success With Fiber Food Introduction in Short Bowel Syndrome N/A